EUVIMEDEUVIMED entdecken
Metaanalyse

Glucagon‐like peptide‐1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta‐analysis and meta‐regression

Frederick Berro Rivera iD, Grace Nooriza O Lumbang, Danielle Rose Magno Gaid, Linnaeus Louisse A Cruz, John Vincent Magalong, Nathan Ross B Bantayan, Kyla M Lara-Breitinger, Martha Gulati, George Bakris iD

Diabetes, Obesity and Metabolism · 2024-06 · 26 (6) · 2209-2228

DOI: 10.1111/dom.15529 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 20.03.2024. Verfasst von Frederick Berro Rivera und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Lincoln Medical Center, New York, New York, USA. Hauptthemen laut MEDLINE: Blood Pressure, Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents. Die Arbeit wurde bisher 58-mal zitiert (Crossref) und nennt 98 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

The cardiovascular benefits provided by glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) extend beyond weight reduction and glycaemic control. One possible mechanism may relate to blood pressure (BP) reduction. We aim to quantify the BP‐lowering effects of GLP1‐RAs.

Methods

A comprehensive database search for placebo‐controlled randomized controlled trials on GLP‐1RA treatment was conducted until December 2023. Data extraction and quality assessment were carried out, employing a robust statistical analysis using a random effects model to determine outcomes with a mean difference (MD) in mmHg and 95% confidence intervals (CIs). The primary endpoint was the mean difference in systolic BP (SBP) and diastolic BP. Subgroup analyses and meta‐regressions were done to account for covariates.

Results

Compared with placebo, GLP‐1RAs modestly reduced SBP [semaglutide: MD −3.40 (95% CI −4.22 to −2.59, p < .001); liraglutide: MD −2.61 (95% CI −3.48 to −1.74, p < .001); dulaglutide: MD −1.46 (95% CI −2.20 to −0.72, p < .001); and exenatide: MD −3.36 (95% CI −3.63 to −3.10, p < .001)]. This benefit consistently increased with longer treatment durations. Diastolic BP reduction was only significant in the exenatide group [MD −0.94 (95% CI −1.78 to −0.1), p = .03]. Among semaglutide cohorts, mean changes in glycated haemoglobin and mean changes in body mass index were directly associated with SBP reduction.

Conclusion

Patients on GLP‐1RA experienced modest SBP lowering compared with placebo. This observed effect was associated with weight/body mass index reduction and better glycaemic control, which suggests that BP‐lowering is an indirect effect of GLP‐1RA and unlikely to be responsible for the benefits.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood PressureDiabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsHumansExenatideGlucagon-Like PeptidesImmunoglobulin Fc FragmentsLiraglutideRandomized Controlled Trials as TopicRecombinant Fusion ProteinsSemaglutide

Stichwörter der Autor:innen

blood pressuredulaglutideexenatideglucagon‐like peptide‐1 receptor agonistsliraglutidesemaglutide

Substanzen

ExenatideGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like PeptidesHypoglycemic AgentsImmunoglobulin Fc FragmentsLiraglutideRecombinant Fusion ProteinsSemaglutidedulaglutide

Autor:innen und Institutionen

  • Department of Medicine, Lincoln Medical Center, New York, New York, USA.
  • Cebu Institute of Medicine, Cebu City, Philippines.
  • University of the Philippines College of Medicine, Manila, Philippines.
  • Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Cardiology, Barbra Streisand Women's Heart Center, Cedars-Sinai Smidt Heart Institute, Los Angeles, California, USA.
  • Department of Medicine, University of Chicago, Chicago, Illinois, USA.

ORCID-Profile: Frederick Berro Rivera, George Bakris

Zitieren

APA

Rivera, F. B., Lumbang, G. N. O., Gaid, D. R. M., Cruz, L. L. A., Magalong, J. V., Bantayan, N. R. B., Lara-Breitinger, K. M., Gulati, M., & Bakris, G. (2024). Glucagon‐like peptide‐1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta‐analysis and meta‐regression. Diabetes, Obesity and Metabolism, 26(6), 2209-2228. https://doi.org/10.1111/dom.15529

Vancouver

Rivera FB, Lumbang GNO, Gaid DRM, Cruz LLA, Magalong JV, Bantayan NRB, et al. Glucagon‐like peptide‐1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta‐analysis and meta‐regression. Diabetes, Obesity and Metabolism. 2024;26(6):2209-2228. doi:10.1111/dom.15529

BibTeX
@article{Rivera2024,
  author = {Rivera, Frederick Berro and Lumbang, Grace Nooriza O and Gaid, Danielle Rose Magno and Cruz, Linnaeus Louisse A and Magalong, John Vincent and Bantayan, Nathan Ross B and Lara-Breitinger, Kyla M and Gulati, Martha and Bakris, George},
  title = {Glucagon‐like peptide‐1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta‐analysis and meta‐regression},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  volume = {26},
  number = {6},
  pages = {2209--2228},
  doi = {10.1111/dom.15529}
}
Kostenlos starten →